ImmunoGen Appoints Stuart A. Arbuckle to Board of Directors
January 24 2018 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced the appointment of Stuart A. Arbuckle to its Board
of Directors. Mr. Arbuckle is replacing Howard Pien, who is
stepping down from ImmunoGen’s Board after eight years of
service.
“We are grateful for Howard’s many contributions to ImmunoGen
over the last eight years,” stated Stephen McCluski, ImmunoGen’s
Chairman of the Board. “His counsel on a range of strategic issues
has been instrumental as we’ve strengthened our leadership in ADCs
and progressed our pipeline of novel candidates through clinical
development. We value Howard’s collaboration and contributions to
the Board and wish him continued success in his endeavors outside
of ImmunoGen.”
“Stuart joins ImmunoGen’s Board at a pivotal moment in the
Company’s evolution,” Mr. McCluski continued. “His international
commercial expertise will be vital as we continue to advance
mirvetuximab soravtansine in the FORWARD I registration trial,
accelerate the development of our earlier-stage ADC assets, and
evolve into a business with marketed products.”
Mr. Arbuckle has more than 30 years of experience in building
biopharmaceutical commercial organizations and has served as
Vertex’s Executive Vice President and Chief Commercial Officer
since 2012, leading the successful global launches of Kalydeco® and
Orkambi®. Prior to joining Vertex, Mr. Arbuckle held multiple
commercial leadership roles at Amgen, Inc., most recently serving
as Vice President and Regional General Manager overseeing the
expansion of the company’s presence in Japan, Asia, the Middle
East, and Africa. As Vice President and General Manager of Amgen’s
Oncology Business Unit, he was responsible for sales and marketing
efforts for Aranesp®, Neulasta® and NEUPOGEN®, and led the
successful launches of XGEVA® and Nplate®. Prior to Amgen, Mr.
Arbuckle held commercial roles of increasing responsibility at
Celltech Pharmaceuticals and GlaxoSmithKline. He also previously
served as a member of Cerulean Pharma’s Board of Directors. He is
currently a national board member of the Cancer Support Community,
a member of the Executive Committee and Health Section Governing
Board for the Biotechnology Innovation Organization (BIO), and is
co-chair of the BIO Standing Committee on Access and Value. Mr.
Arbuckle has a degree in pharmacology and physiology from the
University of Leeds in the United Kingdom.
Mr. Arbuckle stated, “ImmunoGen embarked on a journey last year
to focus on its highest value programs and develop into a fully
integrated biotech company. I’m delighted to offer my insights and
work with this Board as ImmunoGen drives long-term value creation
and moves towards commercializing its first product.”
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted cancer therapeutics using its proprietary ADC
technology. The Company’s lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in a Phase 1b/2
trial in combination regimens for earlier-stage disease. ImmunoGen
has three additional clinical-stage product candidates, two of
which are being developed in collaboration with Jazz
Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's
marketed product, Kadcyla®, and in programs in development by
Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi
and Takeda. More information about the Company can be found at
www.immunogen.com.
Kalydeco®, Orkambi®, Aranesp®, Neulasta®, NEUPOGEN®, XGEVA®,
Nplate®, and Kadcyla® are registered trademarks of their respective
owners.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to preclinical
and clinical studies, their timings and results. A review of these
risks can be found in ImmunoGen's Transition Report on Form 10-KT
for the six-month transition period ended December 31, 2016 and
other reports filed with the Securities and Exchange
Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180124005182/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Courtney O'Konek,
781-895-0600courtney.okonek@immunogen.comorFTI Consulting,
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024